生长激素轴 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-12. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
A variety of circumstances and drugs have been found to affect oxytocin levels in humans. Labor, breastfeeding, pregnancy, hypoglycemia, sexual self-stimulation, physical activity, and psychosocial stress all increase oxytocin levels in humans. Oxytocin levels increase 3- to 4-fold during pregnancy and increase a further 3- to 4-fold during labor. They also increase by 5-fold during breastfeeding. In premenopausal women, oxytocin levels are almost twice as high during ovulation and the luteal phase than during the follicular phase. Oxytocin levels are higher, by about 2-fold, in new romantic relationships. Levels of oxytocin are lower in underweight women with anorexia nervosa, returning to normal with recovery. Estrogens such as estradiol and ethinylestradiol have been found to dose-dependently and robustly increase oxytocin levels in humans. In addition, they have been found to increase the expression of the oxytocin receptor in the brain. Controlled ovarian hyperstimulation can increase estradiol levels by around 90-fold and oxytocin levels by about 6.5-fold. Increased estrogen levels are thought to be involved in the increases in oxytocin levels during the ovulatory and luteal phases, during pregnancy, and in the premenopause compared to the postmenopause. Whereas estrogens unambiguously stimulate oxytocin production, findings appear to be mixed on the influence of androgens such as testosterone on oxytocin production and oxytocin receptor expression.
Infrequent ADRs associated with the use of lidocaine include: hypotension, bradycardia, arrhythmias, cardiac arrest, muscle twitching, seizures, coma, and/or respiratory depression. It is generally safe to use lidocaine with vasoconstrictors such as adrenaline, including in regions such as the nose, ears, fingers, and toes. While concerns of tissue death, if used in these areas, have been raised, the evidence does not support these concerns. The use of lidocaine for spinal anesthesia may lead to an increased risk of transient neurological symptoms, a painful condition that is sometimes experienced immediately after surgery. There is some weak evidence to suggest that the use of alternative anesthetic medications such as prilocaine, procaine, bupivacaine, ropivacaine, or levobupivacaine may decrease the risk of a person developing transient neurological symptoms. Low-quality evidence suggests that 2‐chloroprocaine and mepivacaine when used for spinal anesthetic have a similar risk of the person developing transient neurological symptoms as lidocaine.
In the case of bleeding on probing, which is a diagnostic tool for dentists to routinely check the condition of the gums, the periodontal probe, when inserted gently into the gingival sulcus, is used to measure the depth of the periodontal pocket but upon contact with the sulcular epithelium, should not cause bleeding in individuals with good gingival health. This is due to the resiliency of the sulcular epithelium that has a healthy thickness with a strong underlying collagen architecture. Sites with greater inflammation tend to have more cells yet possess a weaker collagen architecture, making bleeding on probing more noticeable, which is a common finding in stage 2 (early) gingivitis. This highlights the importance of the sulcular epithelium as a physical barrier to protect the underlying connective tissue. When its surface is ulcerated and discontinuous, it allows bacteria to enter more easily. In fact, the total area where bacteria can come in contact with the affected gum tissue is estimated to be as large as the palm of an adult’s hand. Once in the established lesion stage of gingivitis, collagen depletion continues as more polymorphonuclear (PMN) cells seep into the gingival sulcus and infiltrate the spaces within the sulcular epithelium. Permeability of the gingival sulcus (sulcular epithelium & junctional epithelium) also increases with the progress of gingival inflammation.
The first pass effect (FPE), also known as first-pass metabolism (FPM) or presystemic metabolism, is a phenomenon of drug metabolism at a specific location in the body which leads to a reduction in the concentration of the active drug before it reaches the site of action or systemic circulation. The effect is most associated with orally administered medications, but some drugs still undergo first-pass metabolism even when delivered via an alternate route (e.g., IV, IM, etc.). During this metabolism, drug is lost during the process of absorption which is generally related to the liver and gut wall. The liver is the major site of first pass effect; however, it can also occur in the lungs, vasculature or other metabolically active tissues in the body. Notable drugs that experience a significant first pass effect are buprenorphine, chlorpromazine, cimetidine, diazepam, ethanol (drinking alcohol), imipramine, insulin, lidocaine, midazolam, morphine, pethidine, propranolol, and tetrahydrocannabinol (THC). First-pass metabolism is not to be confused with phase I metabolism, which is a separate process.
Sources: en.wikipedia.org
=== Generic names === Bicalutamide is the generic name of the drug in English and French and its INNTooltip INN, USANTooltip United States Adopted Name, USPTooltip United States Pharmacopeia, BANTooltip British Approved Name, DCFTooltip Dénomination Commune Française, AANTooltip Australian Approved Name, and JANTooltip Japanese Accepted Name. It is also referred to as bicalutamidum in Latin, bicalutamida in Spanish and Portuguese, bicalutamid in German, and bikalutamid in Russian and other Slavic languages. The "bica-" prefix corresponds to the fact that bicalutamide is a bicyclic compound, while the "-lutamide" suffix is the standard suffix for NSAAs. Bicalutamide is also known by its former developmental code name ICI-176,334.
== Substrate depletion == In 2022, it was discovered that aminoacyl-tRNA synthetases may incorporate alternative amino acids during shortages of their precursors. In particular, tryptophanyl-tRNA synthetase (WARS1) will incorporate phenylalanine during tryptophan depletion, essentially inducing a W>F codon reassignment. Depletion of the other substrate of aminoacyl-tRNA synthetases, the cognate tRNA, may be relevant to certain diseases, e.g. Charcot–Marie–Tooth disease. It was shown that CMT-mutant glycyl-tRNA synthetase variants are still able to bind tRNAGly but fail to release it, leading to depletion of the cellular pool of glycyl-tRNAGly, what in turn results in stalling of the ribosome on glycine codons during mRNA translation.
The antibody selectively binds to protein A/G, so a high level of purity (generally >80%) is obtained. The generally harsh conditions of this method may damage easily damaged antibodies. A low pH can break the bonds to remove the antibody from the column. In addition to possibly affecting the product, low pH can cause protein A/G itself to leak off the column and appear in the eluted sample. Gentle elution buffer systems that employ high salt concentrations are available to avoid exposing sensitive antibodies to low pH. Cost is also an important consideration with this method because immobilized protein A/G is a more expensive resin. To achieve maximum purity in a single step, affinity purification can be performed, using the antigen to provide specificity for the antibody. In this method, the antigen used to generate the antibody is covalently attached to an agarose support. If the antigen is a peptide, it is commonly synthesized with a terminal cysteine, which allows selective attachment to a carrier protein, such as KLH during development and to support purification. The antibody-containing medium is then incubated with the immobilized antigen, either in batch or as the antibody is passed through a column, where it selectively binds and can be retained while impurities are washed away. An elution with a low pH buffer or a more gentle, high salt elution buffer is then used to recover purified antibody from the support.
== Other controversies == Other proceedings are active before Australian courts regarding Dank's supply of thymosin beta on sportsmen. Findings were made that he supplied the drug to a Mr Earl by the Administrative Appeals Tribunal in 2015; these proceedings are subject to appeal, but were noted by the Court of Arbitration for Sport in their findings regarding the Essendon Football Club doping scandal. In July 2016, Dank was targeted by a drive-by shooting attack that injured him. In 2017, it was reported that Dank entered bankruptcy.
One of the main factors driving the Mexican drug war is widespread poverty. From 2004 to 2008, the portion of the population who received less than half of the median income rose from 17% to 21%, and the proportion of the population living in extreme or moderate poverty rose from 35% to 46% (52 million persons) between 2006 and 2010. Among the OECD countries, Mexico has the second-highest economic disparity between the extremely poor and the rich. The bottom ten percent in the income hierarchy has 1.36% of the country's resources, whereas the upper ten percent has almost 36%. The OECD also notes that Mexico's budgeted poverty alleviation and social development expenses are only about a third of the OECD average. In 2012, it was estimated that Mexican cartels employed over 450,000 people directly, and a further 3.2 million people's livelihoods depended on various parts of the drug trade. In cities such as Ciudad Juárez, up to 60% of the economy depended on illegal sources of income. As of 2023, an estimated 175,000 people are working for the cartels. The head of the U.S. Drug Enforcement Administration (DEA) reported that there are an estimated 45,000 members, associates, and brokers spread over more than 100 countries working under the Sinaloa cartel and the Jalisco New Generation cartel.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.